Medicinal composition containing azilsartan

A composition and drug technology, applied in the field of medicine, to achieve the effects of reduced incidence, increased treatment compliance, and significant synergy

Inactive Publication Date: 2012-07-18
JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD
View PDF6 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since azilsartan is insoluble in wa...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing azilsartan
  • Medicinal composition containing azilsartan
  • Medicinal composition containing azilsartan

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment one prepares azilsartan / indapamide capsule

[0023]

[0024] Process: Prepared according to the conventional process.

Embodiment 2

[0025] Example 2 Preparation of Micronized Azilsartan / Indapamide Capsules

[0026]

[0027] Process: Prepared according to the conventional process. Wherein the volume average particle size of micronized azilsartan is 8.6 μm.

Embodiment 3

[0028] Example 3 Comparison of Dissolution Rates Containing Azilsartan and Micronized Azilsartan

[0029] The capsules containing Azilsartan (prepared as described in Example 1), and the capsules containing micronized Azilsartan (prepared as described in Example 2) were put into the dissolution apparatus respectively, and the paddle method was adopted, and the rotating speed was Set at 50 rpm, the dissolution medium is 1000mL 0.1N HCl, the temperature is fixed at 37°C±0.5°C, and the dissolution test is carried out. The absorption value was measured by an ultraviolet spectrophotometer, and the detection wavelength was 245nm, and the dissolution rate was calculated. The result is as figure 1 As shown, the dissolution rate of capsules containing azilsartan was less than 10% in 60 minutes, while the dissolution rate of capsules containing micronized azilsartan exceeded 80% in 30 minutes. It shows that micronization can improve the dissolution of azilsartan from oral formulations...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Volume average particle sizeaaaaaaaaaa
Volume average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to a medicinal composition containing azilsartan. The medicinal composition contains azilsartan, hydragogue and pharmaceutically-acceptable auxiliary materials. According to the medicinal composition, the azilsartan has the superiority in a dissolving-out aspect and has an obvious synergistic effect under the condition of combining the azilsartan and the hydragogue, and the dose can be reduced.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing azilsartan, which belongs to the technical field of medicine. Background technique [0002] Hypertension is a common type of cardiovascular and cerebrovascular diseases, and there are more than 1 billion hypertensive patients worldwide. The prevalence of hypertension in my country is also on the rise. It is estimated that there are currently 200 million hypertensive patients in the country. High prevalence creates a large market. In the huge market of antihypertensive drugs, non-peptide angiotensin II (Ang II) receptor inhibitors (ARBs, referred to as "sartans") have stable blood pressure reduction, good curative effect, long acting time, and patient tolerance. It has good acceptance, especially has advantages in preventing stroke, delaying renal insufficiency in diabetic and non-diabetic nephropathy, improving left ventricular hypertrophy, and protecting target organs, and has more sid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/4245A61K9/14A61P9/12A61P7/10A61K31/404
Inventor 李玲华苏张连第许向阳
Owner JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap